Media Articles Related to Exelon (Rivastigmine)
Modified stem cells may offer way to treat Alzheimer's disease
Source: Neurology / Neuroscience News From Medical News Today [2014.04.16]
Genetically modified stem cells showed beneficial effects when transplanted into the brains of mice with symptoms and neurological hallmarks of Alzheimer's disease.
Researchers at the University of Valencia discover new molecules against Alzheimer's disease
Source: Biology / Biochemistry News From Medical News Today [2014.04.14]
Researchers of the Unit of Medicine Design and Molecular Topology (Department of Physics Chemistry) of the University of Valencia (UV) have discovered eight new active molecules against Alzheimer's...
New dementia care models to improve care for older adults with Alzheimer's disease
Source: Anxiety / Stress News From Medical News Today [2014.04.10]
The number of older adults with dementia in the United States is forecast to more than double over the next 40 years.
Anavex reports predicted clinical effect of both ANAVEX 2-73 and ANAVEX PLUS in a humanized cortical cognitive model for Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.03.31]
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of...
Alzheimer's Disease Patient Caregiver Guide
Source: MedicineNet Dementia Specialty [2014.03.26]
Title: Alzheimer's Disease Patient Caregiver Guide
Category: Diseases and Conditions
Created: 8/26/2008 12:00:00 AM
Last Editorial Review: 3/26/2014 12:00:00 AM
Published Studies Related to Exelon (Rivastigmine)
Rivastigmine as alternative treatment for refractory REM behavior disorder in
Parkinson's disease. 
disease in whom conventional therapy failed... CONCLUSIONS: The results of this pilot trial need to be confirmed by further
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. [2011.12]
OBJECTIVES: The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline... CONCLUSIONS: Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population. Copyright (c) 2010 John Wiley & Sons, Ltd. Copyright (c) 2010 John Wiley & Sons, Ltd.
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
CONCLUSION: There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. [2011.04]
OBJECTIVE: In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items... CONCLUSIONS: These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright (c) 2010 John Wiley & Sons, Ltd.
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. [2011.02]
BACKGROUND: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD)... CONCLUSION: Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.
Clinical Trials Related to Exelon (Rivastigmine)
A Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelon�) Administration in Young Healthy Male Volunteers [Not yet recruiting]
Rivastigmine is a carbamate, approved by the FDA for the treatment of mild to moderate
dementia associated with Alzheimer's and Parkinson's diseases. Studies conducted in the
Israel Institute of Biological Research (IIBR) have yielded encouraging results in utilizing
rivastigmine pre-treatment as an alternative to pyridostigmine in partially protecting
against organophosphate poisoning, particularly protecting the central nervous system.
The target population for this indication may consist of otherwise healthy people (e. g.
soldiers). Although the treatment regimen has not been established yet it is assumed, based
on animal experiments, that rivastigmine is likely to be administered in repeated doses. In
this setting, further evaluation of the drug's effects and pharmacokinetics in young healthy
subjects is warranted.
The objectives of this study are: 1) To assess the safety and tolerability of repeated
rivastigmine administration (1. 5 mg and 3 mg) in young healthy male volunteers; 2) To
determine the pharmacokinetic profile of rivastigmine (1. 5 mg and 3 mg) following a single
and multiple dose administrations; 3) To assess the extent of blood ChE inhibition following
a single and multiple administrations of rivastigmine and 4) To correlate physiological and
behavioral effects with blood rivastigmine concentrations and blood ChE inhibition in these
This double-blind, placebo-controlled study will be divided in 3 identical periods, preceded
with a two-day initial training in performing cognitive performance tests. Each period will
consist of in-house confinement for 5 days in which rivastigmine will be administered 5
times at an interval of 12 hours. During each period, each subject will receive either
rivastigmine 1. 5 mg X 5, or either rivastigmine 3. 0 mg X 5 or placebo X 5. The treatment in
each period will be randomly assigned in a crossover manner. Rivastigmine pharmacokinetics
will and acetylcholinesterase inhibition will be assessed after the first and the last dose
of each period and will be correlated with physiological and cognitive parameters:
performance tests, visual functions, peak airway flow, saliva production (sialometry) and
The emergence of adverse events will be monitored throughout the study
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients [Recruiting]
The purpose of this study is to determine whether a exercise program when combined with
rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone
would improve quality of life, ability to perform activities of daily living (ADL) and
cognition in patients with Alzheimer's disease.
Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug
treatment to improve quality of life of alzheimer's disease patients.
H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug
treatment to improve quality of life of alzheimer's disease patients, with an expectative of
15% of improvement in the quality of life scale measurement
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence [Recruiting]
The purpose of this study is to determine the safety and effects of rivastigmine and
huperzine A (HupA), potential treatments for cocaine abuse, when used before experimental
administration of cocaine, on a number of physical and psychological measures.
Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients [Recruiting]
The investigators plan to see what factors can influence the durability of Exelon patch
treatment in Korean patients with Alzheimer's disease.
Based on these results, the investigators will find the ways to maximize the effect and
durability of Exelon patch on Korean patients with Alzheimer's disease.
After finishing this study, the investigators are going to present the study results at the
international and national academic meetings or conferences.
Also the investigators expect that they can publish the result in a journal of in the field
of neurology or dementia till the winter of 2010.
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia [Recruiting]
This phase IIIb study is intended to implement a consistent treatment way for switching to
Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of
(1) advantages of transdermal patch over conventional oral therapies: smooth drug delivery
with reduced side effects;(2) encourage treatment compliance in the Alzheimer's dementia
This study is a single-arm, treatment-switched design. Eligible patients, who are under
Exelon capsule 3 mg b. i.d. treatment for 4 weeks before Visit 2, will be recruited, followed
by treatment switch from oral capsule to patch for 48 weeks maintenance treatment. During
the maintenance period, the treatment will be initiated with Exelon Patch 4. 6 mg/24 hours
(Exelon Patch 5 cm2) for the first 24 weeks and the dose will be escalated to Exelon Patch
9. 5 mg/24 hours (Exelon Patch 10 cm2) for another 24 weeks if well tolerated. Visits to
assess safety are scheduled at baseline, 3 days, 1 week and 2 weeks after the first
treatment switch, every 4 weeks until Week 40, and at the end of study (Week 52). The
assessment to address the primary objective will focus on the safety of treatment switching
(Week 0~28); however the safety assessment will be performed during the whole study period.
Reports of Suspected Exelon (Rivastigmine) Side Effects
Cerebrovascular Accident (69),
Dementia Alzheimer's Type (63),
Confusional State (57), more >>